|
Baseline characteristics
|
|
Age <70 y (vs. ≥70 y)
|
0.749 (0.343–1.429)
|
0.380
| | |
|
Sex, male (vs. female)
|
0.634 (0.307–1.308)
|
0.217
| | |
|
HCV infection (vs. other etiology)
|
1.796 (0.964–3.348)
|
0.065
| | |
|
Child Pugh = 5 (vs. ≥6)
|
0.511 (0.271–0.962)
|
0.038
| | |
|
TMN stage III (vs. IV)
|
0.672 (0.357–1.264)
|
0.218
| | |
|
Vascular invasion – (vs. +)
|
0.355 (0.178–0.710)
|
0.003
|
0.382 (0.186–0.786)
|
0.009
|
|
Tumor size <50 mm (vs. ≥50 mm)
|
0.777 (0.412–1.466)
|
0.432
| | |
|
Previous curative therapy: Yes (vs. No)
|
0.433 (0.226–0.829)
|
0.012
| | |
|
AFP <100 (vs. ≥100)
|
1.048 (0.561–1.961)
|
0.954
| | |
|
DCP <1000 (vs. ≥1000)
|
0.473 (0.509–0.912)
|
0.025
|
0.509 (0.261–0.993)
|
0.048
|
|
Initial dose of sorafenib 800 mg (vs. <800 mg)
|
0.744 (0.388–1.426)
|
0.373
| | |
|
HRQOL domain scores ≥40:b
|
|
Physical functioning
|
0.956 (0.509–1.799)
|
0.889
| | |
|
Role physical
|
0.771 (0.416–1.429)
|
0.408
| | |
|
Bodily pain
|
1.582 (0.728–3.436)
|
0.247
| | |
|
General health
|
1.034 (0.516–2.070)
|
0.926
| | |
|
Vitality
|
1.534 (0.631–3.731)
|
0.346
| | |
|
Social functioning
|
0.395 (0.185–0.840)
|
0.016
|
0.452 (0.206–0.995)
|
0.049
|
|
Role emotional
|
0.898 (0.455–1.770)
|
0.755
| | |
|
Mental health
|
0.833 (0.379–1.828)
|
0.649
| | |
